COPA, an Automated Medication Dispensing and Remote Management System for at Home Methadone Dispensing

摘要 美沙酮维持减少和/或消除阿片类药物的使用，降低死亡率 与阿片类药物使用相关的犯罪行为，并允许患者改善他们的健康和社会 生产力此外，参加美沙酮维持治疗（MMT）可以减少 与阿片类药物注射有关的传染病的传播，如肝炎和艾滋病毒。 正在开发计算机化口服处方管理系统装置 作为自动口服液分配系统。COPA专门设计用于输送液体 口服受控和非受控药物给经确认的预期用户。虽然需要 COPA始于阿片类药物流行病，其不良后果在过去几年中不断升级。 二十年来，更迫切需要一种支持阿片类药物使用障碍的家用设备 (OUD)新冠肺炎疫情爆发时出现的患者。大流行病限制了 获得美沙酮维持治疗/治疗阿片类药物治疗方案， 和美国农村地区。COPA装置主要应用于家庭美沙酮 维持治疗，基于该设备的创新双重生物识别确认， 病人的指纹和牙列在药物输送之前。我们建议设计，工程师和 人为因素测试了增强COPA原型并提交FDA De Novo批准。

ABSTRACT Methadone maintenance reduces and/or eliminates the use of opioids, reduces the death rates and criminality associated with opioid use, and allows patients to improve their health and social productivity. In addition, enrollment in Methadone Maintenance Treatment (MMT) can reduce the transmission of infectious diseases associated with opioid injection, such as hepatitis and HIV. The Computerized Oral Prescription Administration System (COPATM) device is being developed as an automated oral liquid dispensing system. COPA is specifically designed to deliver liquid oral controlled and non-controlled medications to the validated Intended User. While the need for COPA began with an opioid epidemic with adverse consequences that have escalated in the last two decades, an even more urgent need for a take-home device supporting opioid use disorder (OUD) patients emerged at the onset of the COVID-19 pandemic. The pandemic has limited access to methadone maintenance therapy/treatment at opioid treatment programs in both urban and rural sections of the US. The COPA device has a major application to at-home methadone maintenance treatment, based upon the device's innovative dual biometric confirmation of both the patient's fingerprint and dentition before delivery of drug. We propose to design, engineer and human factor test an enhanced COPA prototype and submit it for FDA De Novo approval.